

Chattanooga Multiple Myeloma Networking Group

AUGUST 2020

Meeting begins at 6:00 p.m.

Agenda

- Welcome
- New Treatment Approval
- Upcoming Webinars
- Member Updates

AUGUST 2020



New Treatment Approved

Antibody

Drug

Conjugate


What does it mean & How does it work?

New Treatment Approved

What does that mean: combines a monoclonal antibody and a chemotherapy drug

New Treatment Approved

How does it work: uses a monoclonal antibody to target BCMA on the myeloma cell to deliver the toxic payload (chemotherapy) directly to the myeloma cell



New Treatment Approved

How do ADCs work?

<https://youtu.be/KxIPGfbst2c>

BLENREP
Belantamab
Mafodotin

also known as
Bela

Developed and marketing by
GSK

Who can take it?

Must have had at least 4 prior
therapies including:

anti-CD38 monoclonal antibody
Darzalex, Empliciti, or Sarclisa

proteasome inhibitor
Velcade or Kyprolis

immunomodulatory agent
Revlimid or Pomalyst

BLENREP
Belantamab
Mafodotin

How is it given?

Given by IV (30 min.
infusion) every 3 weeks

BLENREP
Belantamab
Mafodotin

What are the side effects?

Study results showed that eye issues occurred in 77% of the 218 patients.

The eye issues included:

Keratopathy (76%) – disorder of cornea
Changes in visual acuity (55%),
Blurred vision (27%),
Dry eye (19%).

Keratopathy means changes in the corneal epithelium as seen on eye examination, which can show with or without symptoms.

Patients who stopped therapy in the study due to eye issues was 2.1%. Low platelet counts were also seen in 69% of patients.

BLENREP

Belantamab

Mafodotin

REMS program
monitors side effects

Participation required
for patients and
treating physicians

How are the side effects managed?

Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Use of eye drops has benefits.

Perform baseline examinations within 3 weeks prior to the first dose.

Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose.

Withhold BLENREP until improvement and resume at same or reduced dose, or consider permanently discontinuing based on severity.

Upcoming Webinars

Family Patient Webinar:

Presented by International Myeloma Foundation
Saturday, August 15 4 – 6 p.m. myeloma.org

Minimum Residual Disease (MRD):

Presented by Multiple Myeloma Research Foundation
Wednesday, August 19 1 – 2 p.m. themmrf.org

Upcoming Webinars

Belantamab Mafodotin and CELMoDs Webinar

Presented by Myeloma Crowd

Saturday, August 22 12 – 1:30 p.m.

myelomacrowd.org

Member Updates

What's new with you?